Aqueous suspensions of ciclesonide for nebulisation

Title: Aqueous suspensions of ciclesonide for nebulisation

Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Cyclopentanohydrophenanthrene Ring System Doai, Hetero Ring Containing, -o-c-o- Is Part Of A Hetero Ring (e.g., Acetonide, Etc.)

Brief Patent Description - Full Patent Description - Patent Claims

The Patent Description & Claims data below is from USPTO Patent Application 20070117783, Aqueous suspensions of ciclesonide for nebulisation.

1. A method for preparing a sterile aqueous suspension of ciclesonide suitable for nebulization comprising the steps of: a. providing an aqueous suspension of ciclesonide, containing one or more pharmaceutically acceptable excipients, which one or more excipients are all non-ionic excipients; and b. autoclaving the aqueous suspension provided in (a).

2. A method for preparing a sterile aqueous suspension of ciclesonide suitable for nebulization comprising the steps of: a. providing an aqueous suspension of ciclesonide, containing at least one non-ionic agent for adjusting osmolality and optionally further pharmaceutically acceptable excipients; and b. autoclaving the aqueous suspension provided in (a).

3. The method according to claim 1, wherein ciclesonide is selected from the group consisting of [11.beta.,16.alpha.(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-- 21-(2-methyl-1-oxopropoxy)pregna-1,4diene-3,20-dione, mixtures of the compounds [11.beta.,16.alpha.(S)]-16,17-[(cyclohexylmethylene)bis(oxy)]-1- 1-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione) and [11.beta.,16.alpha.(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-- 21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione in any desired mixing ratio, and mixtures of the compounds [11.beta.,16.alpha.(S)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-- 21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione) and [11.beta.,16.alpha.(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-1-hydroxy-2- 1-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione consisting essentially of R epimers.

4. The method according to claim 1, wherein ciclesonide is selected from the group consisting of ciclesonide, solvates of ciclesonide, physiologically functional derivatives of ciclesonide, solvates of physiologically functional derivates derivatives of ciclesonide and mixtures thereof.

5. The method according to claim 4, wherein the physiologically functional derivative of ciclesonide is selected from the group consisting of 16.alpha.,17-(22R)-cyclohexylmethylenedioxy-11.beta.,21-dihydroxypregna-1- ,4-diene-3,20-dione, 16.alpha.,17-(22S)-cyclohexylmethylenedioxy-11.beta.,21-dihydroxypregna-1- ,4-diene-3,20-dione, and mixtures thereof in any mixing ratio.

6. The method according to claim 1, wherein the mean particle size of ciclesonide is less than 12 .mu.m.

7. The method according to claim 2, wherein the non-ionic agent for adjusting the osmolality is selected from the group consisting of mannitol, glycerol, glucose, lactose, trehalose, sucrose, propylene glycol, sorbitol, xylitol, polyethylene glycol, ethanol, isopropanol, cyclodextrins, derivatives of cyclodextrins and mixtures thereof.

8. The method according to claim 7, wherein the agent for adjusting the osmolality is selected from the group consisting of mannitol, glycerol, glucose and mixtures thereof.

9. The method according to claim 1, wherein the suitable excipients are selected from the group consisting of agents for adjusting osmolality, suspending agents, agents for modifying pH of the suspension, chelating agents, preservatives and mixtures thereof.

10. The method according to claim 2, wherein the suitable excipients are selected from the group consisting of suspending agents, agents for modifying pH of the suspension, chelating agents, preservatives and mixtures thereof.

11. The method according to claim 10, wherein suitable excipients are non-ionic excipients.

12. The method according to claim 9, wherein an agent for modifying the pH of the suspension is present as excipients, which is an organic acid selected from the group consisting of citric acid, tartaric acid, lactic acid and mixtures thereof.

13. The method according to claim 9, wherein the suspending agent is selected from the group consisting of polysorbates, tyloxapol, poloxamers, poloxamines, polyoxyethylene castor oil derivatives, phospholipids, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylalcohol and mixtures thereof.

14. The method according to claim 13, wherein the suspending agents are polyoxyethylene sorbitan fatty acid esters.

15. The method according to claim 1, comprising the steps of a. dissolving the non-ionic excipients or excipients in water; b. optionally filtering the solution; c. homogeneously suspending ciclesonide within the solution and d. autoclaving the aqueous suspension provided in (c).

16. The method according to claim 2, comprising the steps of a. dissolving the non-ionic agent for adjusting the osmolality and optionally other excipients in water; b. optionally filtering the solution; c. homogeneously suspending ciclesonide within the solution; and d. autoclaving the aqueous suspension provided in (c).

17. The method according to claim 1, wherein autoclaving is carried out at a temperature above 90.degree. C.

18. The method according to claim 17, wherein autoclaving is carried out at a temperature above 120.degree. C.

19. The method according to claim 17, wherein autoclaving is carried out at 121.degree. C. for at least 15 minutes.

20. The method according to claim 1, wherein the sterile aqueous suspension of ciclesonide suitable for nebulization has an osmolality in the range of 225-430 mosmol/kg.

21. A sterile aqueous suspension of ciclesonide suitable for nebulization containing one or more pharmaceutically acceptable excipients, which one or more excipients are all non-ionic excipients.

22. A sterile aqueous suspension of ciclesonide suitable for nebulization containing at least one non-ionic agent for adjusting osmolality and optionally further pharmaceutically acceptable excipients.

23. The sterile aqueous suspension according to claim 21, having an osmolality in the range of 225-430 mosmol/kg.

24. The sterile aqueous suspension according to claim 21, wherein the ciclesonide has a mean particle size of less than 12 .mu.m.

25. The sterile aqueous suspension according to claim 22, wherein the non-ionic agent for adjusting the osmolality is selected from the group consisting of mannitol, glycerol, glucose, lactose, trehalose, sucrose, propylene glycol, sorbitol, xylitol, polyethylene glycol, ethanol, isopropanol, cyclodextrins, derivatives of cyclodextrins and mixtures thereof.

26. The sterile aqueous suspension according to claim 25, wherein the agent for adjusting the osmolality is selected from the group consisting of mannitol, glycerol, glucose and mixtures thereof.

27. The sterile aqueous suspension according to claim 21, wherein the suitable excipients are selected from the group consisting of agents for adjusting osmolality, suspending agents, agents for modifying pH of the suspension, chelating agents, preservatives and mixtures thereof.

28. The sterile aqueous suspension according to claim 22, wherein the suitable excipients are selected from the group consisting of suspending agents, agents for modifying pH of the suspension, chelating agents, preservatives and mixtures thereof.

29. The sterile aqueous suspension according to claim 22, wherein suitable excipients are non-ionic excipients.

30. The sterile aqueous suspension according to claim 27, wherein an agent for modifying the pH of the suspension is present as an excipient which is an organic acid selected from the group consisting of citric acid, tartaric acid, lactic acid and mixtures thereof.

31. The sterile aqueous suspension according to claim 27, wherein the suspending agent is selected from the group consisting of polysorbates, tyloxapol, poloxamers, poloxamines, polyoxyethylene castor oil derivatives, phospholipids, hydroxypropylmethylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, methylcellulose, polyvinylpyrrolidone, polyvinylalcohol and mixtures thereof.

32. The sterile aqueous suspension according to claim 31, wherein the suspending agents are polyoxyethylene sorbitan fatty acid esters.

33. An aqueous suspension of ciclesonide for administration by nebulization, wherein the concentration of ciclesonide within the suspension for nebulization is in the range of 0.005% to 0.5% (w/v).

34. The aqueous suspension according to claim 21, wherein the ciclesonide has a mean particle size of less than 12 .mu.m.

35. The aqueous suspension of ciclesonide according to claim 33, which is a sterile suspension.

36. The sterile aqueous suspension according to claim 21 for administration by nebulization, wherein the concentration of ciclesonide within the suspension for nebulization is in the range of 0.005% to 0.5% (w/v).

37. The sterile aqueous suspension according to claim 21 containing as excipients mannitol and polysorbate or glycerol and polysorbate.

38. The sterile aqueous suspension according to claim 37, additionally containing hydrochloric acid or citric acid.

39. A method for the prophylaxis or treatment of a clinical condition in a patient for which a glucocorticosteroid is indicated, which comprises administration of a therapeutically effective amount of a sterile aqueous suspension of ciclesonide according to claim 21.

40. The method according to claim 39, wherein the clinical condition is asthma the patient is a child and the treatment is a continuous treatment regimen and the sterile aqueous suspension of ciclesonide is administered by nebulization.

41. A drug product comprising a sealed container containing a sterile aqueous suspension according to claim 21, and a label indicating administration by nebulization in a continuous treatment regimen.

Brief Patent Description - Full Patent Description - Patent Claims

Click on the above for other options relating to this Aqueous suspensions of ciclesonide for nebulisation patent application.
###

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.
Start now! - Receive info on patent apps like Aqueous suspensions of ciclesonide for nebulisation or other areas of interest.
###

Previous Patent Application:
Inhibitors of epoxide hydrolases for the treatment of inflammation
Next Patent Application:
Treatment of hyperproliferative diseases with anthraquinones
Industry Class:
Drug, bio-affecting and body treating compositions

###

Design/code © 2009 FreshContext LLC/Freshpatents.com. Website Terms and Conditions - Also read: About this Page
Patent data source: patents published by the United States Patent and Trademark Office (USPTO)
Information published here is for research/educational purposes only (and in conjunction with our Keyword Monitor) and is not meant to be used in place of the full USPTO patent document/images or a comprehensive patent archive search. Complete official applications are on file at the USPTO and often contain additional data/images (Freshpatents is currently text-only). FreshPatents.com is not affiliated with or endorsed by the USPTO or firms/individuals or products/designs/ideas related to listed patents.

FreshPatents.com Support
Thank you for viewing the Aqueous suspensions of ciclesonide for nebulisation patent info.
IP-related news and info

Results in 0.11196 seconds

Other interesting Feshpatents.com categories:
Computers: Graphics , I/O , Processors , Dyn. Storage , Static Storage , Printers 174

* Protect your Inventions
* US Patent Office filing

Provisional Patent
Utility Patent

PATENT INFO